Building a Medical Device? 9 Ways Legal Complexity Can Affect Product Innovation

9 Ways Legal Complexity Can Affect Medical Device Innovation

What Happens When a Medical Device Idea Meets Too Many Constraints Too Soon?

Most medical device product development journeys start with a problem, not a product.

A clinician sees the same difficulty during a procedure repeatedly. A founder spots a gap in an existing device. An engineering team realises that an established technology could be applied differently to solve a healthcare problem.

At this point, the possibilities are still wide open.

Then the questions begin.

Who will own the IP? Can this be patented? What happens if an existing technology is used? What can the development partner disclose? Can they work on another product in the same category? What will regulators require?

These are valid questions. Some of them need answers early.

But there is a point at which protecting an idea can begin to restrict the process required to make that idea better.

At Inspire Design, after working across 60+ healthcare product development projects, we have seen one principle come up repeatedly: good product development is not about removing constraints. It is about introducing the right constraint at the right time.

That distinction matters.

India itself is pushing towards a larger medical-device innovation ecosystem. The National Medical Devices Policy 2023 was introduced with an ambition to grow India's medical-device sector from approximately US11billiontoUS50 billion by 2030.

If India wants to create more medical devices rather than simply manufacture them, the conversation also needs to include what happens at the earliest stages of medical device design and development, when an idea is still being explored.

And sometimes, that means knowing when not to close doors too quickly.

1. Medical Device Innovation Needs Room Before It Needs Answers

Early-stage product development is deliberately uncertain.

Suppose a clinician approaches a design team with an idea for improving an existing procedure.

There may be five possible ways to solve it.

One may involve changing the mechanism. Another could change the material. A third could simplify the number of components. A fourth might use an established technology in an entirely different way.

The team's first job shouldn't necessarily be to decide which idea survives.

It should be to understand which ideas deserve to be explored.

This is where excessive constraints can become counterproductive.

If every concept immediately has to pass through every conceivable future legal, commercial, IP and regulatory question, the conversation can subtly change.

Instead of asking:

"What's the best way to solve this clinical problem?"

the team begins asking:

"What are we allowed to design?"

There are, of course, constraints that cannot wait. Patient safety, intended use, fundamental regulatory considerations and significant IP issues may affect the product architecture itself.

But not every question carries the same urgency.

A strong new product development process distinguishes between what must be known today and what must be resolved before the next major decision.

2. Existing Technology and New IP Are Not the Same Thing

This distinction sounds obvious until an actual product starts being developed.

Medical devices rarely emerge from completely new science.

A product may use an existing heating principle, sensing technology, motor, battery, communication protocol, mechanical mechanism or manufacturing process.

The innovation may lie elsewhere.

Perhaps it is how those technologies have been combined.

Perhaps it is the mechanical architecture.

Perhaps it is the clinical application.

Perhaps it is a genuinely new component or mechanism.

That means a single product can contain several different layers of knowledge:

Existing technology.

The client's pre-existing intellectual property.

The development partner's existing know-how.

Third-party components and technology.

Publicly known engineering principles.

New IP created specifically during the project.

Putting all of these into one broad bucket marked “project IP” can create ambiguity.

A much more useful question at the beginning of a medical device design project is:

What existed before we started, and what are we actually creating together?

That clarity protects both sides.

The client gets clarity around what is genuinely being developed for the project. The development team retains clarity around the knowledge, tools and capabilities it already possessed.

Protect what is being created. Clearly identify what already existed.

3. Hypothetical Risk Can Start Shaping a Very Real Product

Medical devices need rigorous risk management.

But there is a difference between identifying risk and designing entirely around hypothetical scenarios.

Consider an early feature that appears valuable during concept development.

Someone asks:

"What if this creates an issue when we enter another market three years from now?"

It's a useful question.

But should that possibility eliminate the feature today?

Maybe.

Maybe not.

The better question is whether the issue needs to change the product now, or whether it needs investigation before the next stage.

Without that distinction, product teams can start making permanent design decisions around problems that may never materialise.

The opposite is equally dangerous: ignoring an issue that will clearly affect classification, safety or product architecture because it feels inconvenient today.

Neither extreme produces good products.

The skill lies in knowing which risks need a decision and which need an investigation.

Neither extreme produces good products.

The skill lies in knowing which risks need a decision and which need an investigation.

4. Eventually, Someone Has to Use the Device

Legal documents don't use medical devices.

People do.

That sounds simplistic, but it is surprisingly easy to lose sight of during a complex medical device development process.

Imagine a device that meets every requirement on paper but is awkward for a clinician wearing gloves.

Or an interface that works beautifully in a quiet design studio but becomes difficult to interpret in a busy hospital.

Or a component that is technically functional but difficult to clean between patients.

Human-factors engineering exists because these interactions matter.

Or an interface that works beautifully in a quiet design studio but becomes difficult to interpret in a busy hospital.

Or a component that is technically functional but difficult to clean between patients.

Human-factors engineering exists because these interactions matter.

FDA guidance on medical-device human factors specifically asks manufacturers to consider the intended users, use environments and user interfaces when designing for safe and effective use. It also recommends that final human-factors validation include at least 15 participants from each distinct user population where different user groups interact differently with the device.

That number isn't a shortcut or universal recipe for usability research. Research examining medical-device usability testing has specifically cautioned that no single cohort size can guarantee that every usability problem will be discovered.

The broader lesson is more useful:

You have to put products in front of representative users.

Documentation can tell you what a device is supposed to do.

Watching someone use it tells you what it actually does in their hands.

5. Ownership and Credibility Don't Have to Be the Same Conversation

This is particularly important when healthcare companies work with external medical device design and development companies.

A client may want ownership of the project-specific IP created for its product.

That can be completely reasonable.

The design partner may also have no expectation of royalties or any continuing commercial ownership of the resulting product.

But there is another question that deserves its own conversation:

Can the design partner ever say that it worked on the project?

For specialist product-development companies, credibility is built through experience.

And when a future client evaluates a design partner, one of the most natural questions is:

"What have you done before?"

There is a significant difference between answering that question and disclosing a client's confidential information.

A design company doesn't need access to future royalties simply to establish that it contributed to a product.

Nor does it necessarily need permission to disclose confidential CAD files, specifications, proprietary technology or commercial information.

Depending on what both parties agree, credibility could mean something much narrower: permission after launch to mention involvement, an approved case study, an anonymised description, or simply a process for requesting permission.

The important part is to have that conversation.

IP ownership, confidentiality and professional credibility are related, but they aren't identical.

Treating them as separate questions can make expectations much clearer.

6. What Happens to Everything a Design Team Learns?

Every engineering project creates a product.

It also creates experience.

An engineer who has worked repeatedly on medical devices develops better judgement around ergonomics, mechanisms, materials, electronics, assembly, tolerances, prototyping, usability, Design for Manufacturing (DFM) and clinical workflows.

That accumulated experience is one of the reasons organisations hire specialist design teams in the first place.

Which creates an interesting tension.

A client needs to know that its confidential information and genuine competitive advantage are protected.

At the same time, a design organisation needs clarity that working on one product does not prevent its engineers from ever applying their general professional expertise to an unrelated future project.

Imagine an engineer works on a device that happens to use a commonly available sensor.

Years later, another product in a completely different clinical category uses the same type of established sensing technology.

The relevant question isn't simply whether both products use a sensor.

It is whether confidential client information or project-specific IP is being reused.

That distinction matters.

Contracts need to be interpreted and drafted by qualified legal professionals. From a product-development standpoint, however, the principle is worth recognising:

Protect confidential knowledge without treating accumulated engineering capability as confidential knowledge.

7. Fear Can Make Products Safer. It Can Also Make Ideas Smaller.

Medical-device development should be cautious.

People's health can depend on these products.

But caution and creativity are not opposites.

Early concept development often benefits from divergent thinking: create possibilities first, then progressively eliminate them using evidence.

Explore → Prototype → Test → Learn → Introduce Constraints → Refine → Validate

When that order gets reversed, teams can default to whatever feels least risky.

The result may be an incremental improvement to an existing solution when a substantially better approach was possible.

This doesn't mean every radical concept deserves to survive.

Most won't.

That's the point of prototyping and testing.

Ideas should ideally be eliminated because the evidence tells us they don't work not simply because they initially feel unfamiliar.

8. The First Prototype Should Be Allowed to Be Wrong

One of the most expensive misconceptions in product development is that an early prototype needs to look like the final product.

It doesn't.

An early medical device prototype has a much more useful job:

Answer a question.

Does the mechanism work?

Can a clinician hold it comfortably?

Is the force sufficient?

Does the interface make sense?

Can the device fit into the existing workflow?

Does the technology behave as expected?

Sometimes a rough prototype that proves an assumption wrong in two weeks is more valuable than a polished prototype that takes three months.

Usability research makes the same point from another direction.

The software research cited in FDA human-factors materials found that a sample of 15 people detected a minimum of 90% and an average of roughly 97% of known usability problems in the particular software studied. FDA guidance cautions against treating that finding as a guarantee for all medical devices, where user interactions and risks can differ considerably.

The important insight isn't the number 15.

It is that people using a product reveal problems that the team designing it may not see.

That's why early concepts need room to be built, challenged and sometimes discarded.

9. So When Should Legal, IP and Regulatory Expertise Enter?

Early.

Just not necessarily all at once, at maximum depth.

At the beginning, there are questions that can fundamentally change the product:

What is its intended use?

Could the likely device classification affect development?

Is there an obvious safety issue?

Does existing IP potentially block the proposed approach?

Will the product handle sensitive data?

Which markets is it ultimately intended for?

Those questions deserve visibility before teams invest heavily in a direction.

As the product becomes clearer, the questions become more detailed.

9 Ways Legal Complexity Shapes Innovation

A useful way to think about the journey is:

Stage	Questions that become important
Clinical problem	Who has the problem? How is it solved today? Is a new product actually needed?
Concept	Intended use, major safety considerations, early IP landscape, likely regulatory pathway
Prototype	Functionality, usability, materials, engineering feasibility, key risks
Design refinement	Verification and validation planning, regulatory requirements, manufacturing feasibility
Design freeze	Testing, documentation, claims, DFM/DFA, compliance requirements
Manufacturing	Tooling, suppliers, quality, repeatability, labelling and production controls
Commercialisation	Market-specific approvals, claims and applicable post-market requirements

This isn't a universal formula.

A simple low-risk device and an implantable or connected diagnostic product will require very different levels of scrutiny

.

The principle is what matters:

Bring expertise early enough to prevent expensive mistakes, but introduce constraints in proportion to what the product actually needs at that stage.

7 Questions Worth Answering Before a Medical Device Development Partnership Begins

By the time a healthcare company and its development partner start working together, some clarity can prevent considerable confusion later.

1. What did each party already bring into the project?

Identify relevant background IP, technology, tools and pre-existing know-how.

2. What are we actually creating through this project?

Define how project-specific deliverables and newly created IP will be treated.

3. What genuinely needs to remain confidential?

Be clear about proprietary information rather than relying only on broad assumptions.

4. Can the project ever be referenced?

If the development partner wants to establish credibility, agree whether there is a future approval mechanism.

5. What restrictions apply after the project?

Make the distinction between genuine competitive restrictions and general professional capability clear.

6. Are there continuing commercial rights or royalties?

If the answer is no, clarity is useful here too.

7. What happens when the product changes?

Because it probably will. Product-development agreements need a practical way to deal with changes in scope and requirements.

These aren't substitutes for legal advice.

They are simply better questions to have on the table before ambiguity becomes disagreement.

How Can Medical Device Companies Balance Innovation and Compliance?

The strongest medical device development process doesn't choose between innovation and compliance. It allows early exploration while identifying safety, IP and regulatory constraints that could fundamentally affect the product. As the design matures, those constraints become progressively more detailed and formal.

In practice, that means resisting two extremes.

"Let's design everything first and worry about the rest later."

is dangerous.

But so is:

"Let's answer every possible future question before we design anything."

One delays essential constraints.

The other can suffocate exploration.

A better principle is:

Explore broadly. Protect specifically. Constrain deliberately.

Speak to an Expert Today

FAQs About IP, Legal and Regulatory Considerations in Medical Device Development

1. Who owns the IP when a design agency develops a medical device?

There is no universal answer. It depends on existing rights and the agreement between the parties. A good agreement should clearly distinguish background IP, existing or third-party technology and new project-specific intellectual property. The specific arrangement should be reviewed by qualified legal professionals.

2. Is existing technology automatically owned by the company developing a new medical device?

Not necessarily. A new product can incorporate established technologies, public knowledge, third-party components and pre-existing IP alongside genuinely new intellectual property. Ownership depends on the underlying rights and contractual arrangements rather than simply on the technology appearing in the finished product.

3. Can a medical device design company show client projects in its portfolio?

Only where the applicable agreement and client permissions allow it. One approach is to agree on an approval process for referencing a project after launch without disclosing confidential or proprietary information.

4. When should regulatory planning begin during medical device development?

Regulatory planning should begin early enough to identify fundamental issues that could affect intended use, classification, safety, product architecture or market access. The depth of regulatory work can then increase as the product becomes more defined.

5. Why is usability important in medical device design?

Medical-device usability can influence safe and effective use. Human-factors engineering considers the intended users, environments and interfaces so that foreseeable use-related problems can be identified and addressed during development.

6. Should a medical device startup think about IP before prototyping?

Potentially, particularly where existing IP or planned disclosure could materially affect the product or protection strategy. The appropriate approach depends on the invention, existing rights and intended markets and should be discussed with qualified IP professionals.

7. Can legal restrictions affect medical device innovation?

They can if restrictions are broader or introduced earlier than the product requires. Conversely, insufficient attention to genuine legal, IP, safety or regulatory constraints can create significant problems later. The objective is to identify which constraints matter at each stage of development.

The Best Medical Device Isn't Designed Without Constraints

It is designed with the right ones.

A good product team needs someone willing to ask:

"What if we tried this?"

It also needs someone willing to ask:

"What could go wrong?"

The magic is not choosing between them.

It is knowing when each question needs to become louder.

At Inspire Design, working across 60+ healthcare product development projects has reinforced this for us repeatedly. A medical device doesn't move neatly from design to engineering to prototyping to manufacturing as four independent exercises.

One decision changes another.

A user insight changes the design.

The design changes the engineering.

Engineering changes manufacturing.

A regulatory requirement may send the team back to the design.

And a prototype can prove that the original assumption was wrong.

That's product development.

Have a medical device idea and already have more questions than answers?

You don't need to solve everything on Day 1

.

You need to know what needs to be solved on Day 1.

Bring us the clinical problem, the sketch, the early prototype or the idea that's still being discussed internally.

At Inspire Design, we help clinicians, healthcare startups and medical-device companies move through product design, engineering, prototyping and manufacturing readiness without losing sight of the problem that started the journey.

Let's figure out what needs to be solved now, what needs to be protected, and what still needs room to be imagined.